Efficacy of Hepatitis B Virus Vaccines HBVaxpro40© and Fendrix© in Patients with Chronic Liver Disease in Clinical Practice

Chronic liver disease results in a low response rate to the hepatitis B virus vaccine. Information on the efficacy of the double adjuvanted vaccine FENDRIX® (3-O-desacyl-4’-monophosphoryl lipid A and aluminum phosphate) and single adjuvant HBVAXPRO®40 (aluminum hydroxyphosphate sulfate) in chronic l...

Full description

Saved in:

Bibliographic Details
Published in:	Vaccines (Basel) 2022-08, Vol.10 (8), p.1323
Main Authors:	Horta, Diana, Forné, Montserrat, Agustí, Anna, Raga, Agnes, Martín-Cardona, Albert, Hernández-Soto, Juana María, Ruiz-Ramírez, Pablo, Esteve-Comas, Maria
Format:	Article
Language:	eng
Subjects:	Age Alcohol Aluminum Aluminum phosphate Antibodies Biopsy Blood tests chronic liver disease Cirrhosis Clinical medicine Complications and side effects Diagnosis Effectiveness Etiology Hepatitis Hepatitis A Hepatitis B hepatitis B vaccination Hepatitis B vaccine HIV Human immunodeficiency virus Hypertension Infections Lipid A Lipids Liver Liver cirrhosis Liver diseases Liver transplants Monophosphoryl lipid A Multivariate analysis Patient outcomes Patients Performance evaluation Review boards Ultrasonic imaging Vaccination Vaccines Viruses
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Chronic liver disease results in a low response rate to the hepatitis B virus vaccine. Information on the efficacy of the double adjuvanted vaccine FENDRIX® (3-O-desacyl-4’-monophosphoryl lipid A and aluminum phosphate) and single adjuvant HBVAXPRO®40 (aluminum hydroxyphosphate sulfate) in chronic liver disease is scarce. The primary aim of this prospective study in clinical practice was to evaluate the effectiveness of HBVAXPRO®40 and FENDRIX® in this setting. Patients received HBVAXPRO® (0, 1 and 6 months) or FENDRIX® (0, 1, 2 and 6 months) depending on availability. Clinical data and anti-HBs levels were collected at 2, 6 and 12 months. A total of 125 patients were included (mean age 61.8 years; 57.6% males; 43.2% liver cirrhosis; 75.9% Child A and 24.1% Child B): 76 were vaccinated with HBVAXPRO® and 49 with FENDRIX®. There were no significant differences between the two vaccines. The overall response rates at 2, 6 and 12 months were 76.8, 72.8 and 59.2%, respectively. In the univariate analysis, active alcohol intake, alcohol etiology, liver cirrhosis and ultrasound signs of portal hypertension were associated with a lower response to vaccination, whereas in the multivariate analysis, liver cirrhosis was the only factor that significantly increased the likelihood of nonresponse (OR 10.5). HBVAXPRO® and FENDRIX® are good options for HBV vaccination in patients with chronic liver disease.
ISSN:	2076-393X 2076-393X